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Regional Citrate Anticoagulation for Intermittent Hemodialysis in
Dogs
T. Francey , and A. Schweighauser
Background: The traditional systemic heparinization used for anticoagulation in extracorporeal therapies may cause fatal
complications in animals at risk of bleeding.
Hypothesis/Objectives: To develop and validate a protocol of regional citrate anticoagulation (RCA) for intermittent
hemodialysis in dogs.
Animals: A total of 172 dogs treated with hemodialysis for acute kidney injury.
Methods: In vitro titration was performed, adding trisodium citrate and calcium chloride to heparinized canine blood. A
tentative protocol was used ﬁrst in 66 treatments with additional heparinization and subsequently in 518 heparin-free treat-
ments. Safety and adequacy of RCA were assessed based on clinical and laboratory monitoring, dialyzer pressure gradient,
treatment completion, and visual scoring of the extracorporeal circuit.
Results: Addition of 1 mmol/L citrate to heparinized blood decreased the ionized calcium concentration by 0.23 mmol/L
(95% conﬁdence interval [CI], 0.16–0.30) and 1 mmol/L calcium increased it by 0.62 mmol/L (95% CI, 0.45–0.79). Heparin-
free treatments were initiated with infusion of trisodium citrate (102 mmol/L) at 2.55 mmol/L blood and calcium chloride
(340 mmol/L) at 0.85 mmol/L. Citrate and calcium administrations were adjusted in 27 and 34% of the treatments, respec-
tively. Overall, anticoagulation was satisfactory in 92% of the treatments, with expected azotemia reduction in 95% (urea)
and 86% (creatinine), stable dialyzer pressure gradient in 82%, and clean extracorporeal circuits in 92% of the treatments.
Eighteen treatments (3.5%) were discontinued prematurely, 9 because of clotting and 9 for reasons unrelated to the RCA
procedure.
Conclusions and Clinical Importance: Regional citrate anticoagulation allows safe and eﬃcient heparin-free hemodialysis
in dogs at risk of bleeding.
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Extracorporeal blood puriﬁcation techniques such ashemodialysis (HD) require anticoagulation of the
circulating blood. The most commonly applied protocol
uses systemic heparinization (SH) with unfractionated
heparin administered ﬁrst as a bolus of 10–50 IU/kg,
followed by a constant rate infusion (CRI) of 50–
100 IU/kg/h.1,2 Heparin infusion rate is based on clini-
cal assessment of evidence or risk of bleeding, and it is
adjusted based on coagulation monitoring every
30–60 minutes during the treatment, with a goal to
approximately double the coagulation time at baseline.1
Systemic anticoagulation, however, can worsen existing
bleeding lesions frequently encountered in the setting of
acute kidney injury (AKI).3 Disseminated intravascular
coagulation, gastro-intestinal ulcerations, or leptospiro-
sis-associated pulmonary hemorrhages can deteriorate
rapidly with a potentially fatal outcome.4,5 Moreover,
SH persists several hours beyond the dialysis treatment,
hindering routine patient care, and potentially urgent
diagnostic, medical, or surgical procedures. This risk of
bleeding is ampliﬁed further in continuous or extended
modes of renal replacement therapy. Although possible,
reversal of heparin with protamine usually is reserved
for emergencies because of the risk of anaphylactic
reactions and of heparin rebound with later recurrence
of bleeding.6
Alternatives to SH have been developed, including
low-heparin or heparin-free therapies with regular saline
ﬂushes of the extracorporeal circuit, fast-short treatment
protocols, use of coated dialyzer membranes, and
hemodiaﬁltration with preﬁlter hemodilution.1,7,8 The
eﬃcacy of these modiﬁed protocols in dogs, however, is
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limited, resulting in increased blood losses, decreased
treatment eﬃcacy, and early failure of extracorporeal
circuits.1,8 Additionally, activation of the coagulation
system in treatments with insuﬃcient anticoagulation
can potentially worsen the thrombotic risk in AKI
patients who frequently are hypercoagulable.3,9
Regional anticoagulation techniques limited to the
blood in the extracorporeal circulation have been devel-
oped for human patients treated with continuous renal
replacement therapies.1,8 In these techniques, the blood
coming from the patient is anticoagulated, and this pro-
cess is reversed in the returning blood, so that the blood
circulating in the body has normal hemostatic charac-
teristics. The most commonly used technique decreases
the ionized calcium concentration (iCa) in the extracor-
poreal circuit by infusing trisodium citrate in the inﬂow
line and restores normocalcemia with calcium chloride
administration in the outﬂow line, before returning the
blood to the patient.10,11 Reliable and suﬃcient extra-
corporeal hypocalcemia (iCa < 0.4 mmol/L) is essential
for eﬀective anticoagulation, and dependable restoration
of normocalcemia is critical for the safety of the patient,
otherwise at risk of hypocalcemic or hypercalcemic
complications. Protocols have been described and used
widely for human patients on continuous therapies, but
only rarely for intermittent HD.12 In animals, protocols
have been described for experimental hemoﬁltration in
sheep and for apheresis in dogs.13,14
The aim of our prospective study therefore was to
develop in vitro and validate in vivo an eﬃcient and
safe protocol of regional citrate anticoagulation (RCA)
for intermittent HD in dogs with AKI.
Materials and Methods
Study Design
The study was designed to ﬁrst obtain in vitro titration data for
citrate and calcium in canine blood to adjust existing protocols
used in humans for use in dogs needing heparin-free HD treat-
ment. In vivo eﬀects on calcium concentration then were evaluated
in pilot dogs anticoagulated with conventional SH, enabling the
use of low citrate and calcium ﬂow rates otherwise insuﬃcient for
anticoagulation. Eﬃcacy and safety of the established RCA proto-
col subsequently were evaluated in dogs using heparin-free HD
treatments in which anticoagulation depended solely on the eﬀect
of citrate. Because most dogs with AKI were diagnosed with lep-
tospirosis and active pulmonary hemorrhage, heparin-free proto-
cols were necessary for safe HD, precluding the possibility of a
comparison group under SH.
Animals
Clinically healthy blood donor dogs with unremarkable history
and physical examination ﬁndings, and normal hematology and bio-
chemistry proﬁle results were enrolled for the in vitro experiments.
For the in vivo study, client-owned dogs diagnosed with AKI and
treated with intermittent HD were included. Acute kidney injury
was deﬁned by the combination of historical, clinical, laboratory, or
imaging evidence, with at least 2 of the following criteria:15,16
(1) presence of renal azotemia with a serum creatinine concentration
≥1.7 mg/dL, persisting at least 24 h after correction of prerenal fac-
tors; (2) increase in serum creatinine concentration ≥0.3 mg/dL
during a 48 h interval in the absence of prerenal factors; (3) persis-
tent pathologic oligoanuria (<1 mL/kg/h over 6 h) after volume
repletion; (4) and evidence of tubular injury with renal glucosuria or
granular casts on urinalysis. Requirement for HD was based on
clinical and laboratory evaluation and assessed for all dogs by 1 of
the 2 authors. Dogs were not excluded if the data indicated evidence
of underlying chronic kidney disease, because this would not neces-
sarily aﬀect their need for dialysis and anticoagulation. To truly rep-
resent the population of dogs requiring renal replacement therapies,
dogs with liver injury or failure also were not excluded, despite
potentially altered hepatic metabolism of citrate. All procedures
were conducted in accordance with the Animal Welfare Act and
subject to informed owner consent.
In vitro Titration of Citrate and Calcium
Venous blood was obtained by clean jugular venipuncture from
healthy dogs and was placed in lithium heparin tubes for titration
experiments. For each dog, trisodium citratea was added to 5 ali-
quots of heparinized blood in concentrations of 1.19–3.50 mmol/L.
In a second step, calcium chlorideb was added to aliquots of each
of these citrated samples in concentrations of 0.43–1.70 mmol/L.
Ionized calcium concentration, other electrolyte concentrations,
and venous blood gases were measured in the initial blood and in
each of the citrated and recalciﬁed samples with a clinical blood gas
analyzer.c
Hemodialysis Procedures
Vascular access was provided by large-bore (7–14 Fr), double-
lumen jugular dialysis catheters adapted to the animal size. Veno-
venous intermittent HD was performed with a Gambro AK200
UltraS system.d The dialysis prescription was tailored and adjusted
to the needs of the dogs, according to recommended protocols.1,2
The extracorporeal circuit consisted of blood tubinge and
dialyzersf chosen mostly based on their priming volumes and mem-
brane characteristics. Dialysate ﬂow rate was 300–700 mL/min,
and dialysate temperature was set at 38.5°C. The dialysate sodium
and bicarbonate concentrations that would have been chosen in
standard treatments with SH were decreased by 5 and 2 mmol/L,
respectively, as recommended in protocols designed for humans to
avoid hypernatremia and metabolic alkalosis.11 Dialysate sodium
concentration ranged from 137 to 150 mmol/L, potassium concen-
tration from 2.0 to 3.2 mmol/L, and bicarbonate concentration
from 20 to 30 mmol/L. Calcium-free dialysateg was used for all
RCA treatments.
The duration of the dialysis procedures, the total volume of
blood treated, and the blood ﬂow rate were determined individu-
ally to reach a urea reduction ratio (URR) of approximately 35,
60, and >75% for the ﬁrst, second, and later treatments, respec-
tively, based on the expected URR modeled from 233 treatments
performed previously with SH on the same dialysis platform.
RCA Protocol
The RCA protocol to be used in vivo was based on the results
of the in vitro experiments for the initial ﬂow rates and on similar
protocols used in humans for monitoring and rate adjustments.
Initial ﬂow rates of trisodium citrate were calculated to decrease
iCa by 0.8 mmol/L, from 1.1 mmol/L (median value in AKI dogs
at the authors’ institution) to a goal of 0.3 mmol/L in the circuit.
Being exposed to a calcium-free dialysate, iCa is further decreased
postﬁlter, and approximately 60% of the calcium citrate complexes
are estimated to be dialyzed from the blood when using standard
dialysis protocols.17 With metabolism of citrate from the remain-
ing complexes, calcium is freed in the circulation, and therefore,
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the initial ﬂow rate of calcium chloride infusion was calculated as
60% of the rate necessary to increase iCa by 0.8 mmol/L, from
0.2 to 1 mmol/L. Commercial solutions of trisodium citrate
(C6H5O73Na, 102 mmol/L)a and calcium chloride (CaCl2,
340 mmol/L)b were used as citrate and calcium sources,
respectively.
A spreadsheeth was designed to facilitate calculation of citrate
and calcium infusion rates as a function of the blood ﬂow rate,
and to compute the ﬂuid volume to be removed by ultraﬁltration
to perform isovolemic HD. Monitoring of iCa was performed
before treatment, after 30 minutes, and at 60–90 minutes intervals
subsequently. For this monitoring, blood was sampled from the
dog (S1), from the extracorporeal circuit predialyzer (S2) and post-
dialyzer (S3). When adjustments of the infusion rates were
required, the corresponding iCa was rechecked 30–60 minutes
later. All samples were collected in lithium heparin tubes and sub-
mitted for iCa, other electrolyte concentrations, and venous blood
gas measurements. The target iCa in the extracorporeal circuit (S2
and S3) was 0.2–0.4 mmol/L and following adjustments to the
citrate infusion rate were planned when the target was not
achieved: 10% when iCa was <0.2 mmol/L, +10% when iCa was
0.4–0.5 mmol/L, and +20% when iCa was >0.5 mmol/L. A + 10%
adjustment was left to the clinician’s discretion for borderline iCa
(0.35–0.4 mmol/L). Target iCa in the dog (S1) was 0.8–1.2 mmol/
L with following adjustments to the calcium infusion rate of +20%
when iCa was <0.6 mmol/L, +10% when iCa was 0.6–0.8 mmol/L,
10% when iCa was 1.2–1.5 mmol/L, and 20% when iCa was
>1.5 mmol/L. A + 10% adjustment was left to the clinician’s dis-
cretion for borderline iCa (0.8–1.0 mmol/L). The last citrate and
calcium ﬂow rates used for a treatment were applied for the initia-
tion of the next treatment in the same dog.
Evaluation of Protocol Safety and Eﬃcacy
Initial validation of the RCA protocol was performed in pilot
HD treatments with additional SH, dissociating the calcium con-
trol from the need of anticoagulation. Further treatments were
performed with the ﬁnal heparin-free protocol using infusions of
citrate and calcium directly at the access catheter. Evaluation of
the eﬃcacy and safety of the protocol, and eﬀects on blood bio-
chemistry and blood gases are reported only for these treatments.
Because SH has no eﬀect on calcium, in vivo calcium changes
upon citrate and calcium injections were evaluated in all treat-
ments, including pilot treatments.
The safety of the procedure was evaluated based on clinical
monitoring, including routine cardiovascular (heart rate, mucous
membranes, indirect oscillometric blood pressure q15 min), respi-
ratory (respiratory rate and type q15 min), and neurologic (menta-
tion, pupillary light responses q30 min) variables. Particular
attention was given to clinical signs potentially associated with
hypocalcemia, including facial rubbing, muscle twitching, and
muscle tremors. Continuous electrocardiographic (ECG) monitor-
ing was maintained for the ﬁrst HD treatment in each dog. The
eﬃcacy of anticoagulation was evaluated based on following crite-
ria: successful completion of the procedure; change in the dialyzer
pressure gradient; eﬀective urea and creatinine reduction ratios
(URR, CrRR); and, visual scoring of the extracorporeal circuit
after blood rinseback (see Appendices S1 and S2). Overall, satis-
faction of anticoagulation was scored as follows: very good, all
eﬃcacy variables satisfactory; minor grade complication, 1 goal
not achieved; moderate grade complication, problems necessitating
adjustments, but treatment performed to completion; severe grade
complication, treatment aborted early due to unsatisfactory
anticoagulation.
Data Analysis and Statistical Methods
Because most data sets were not normally distributed, they are
presented as median (interquartile range, IQR) and analyzed using
nonparametric methods. For comparison of numeric data between
groups, a Wilcoxon Signed-Rank Test was used for paired data, a
Mann-Whitney U-test for unpaired data, and a Kruskal-Wallis
one-way analysis of variance (ANOVA) for >2 groups. A Chi-
square test was used for comparison of proportions between
groups. A P-value <0.05 was considered signiﬁcant. Analyses were
performed using commercial statistical software.i
Results
In vitro Citrate and Calcium Titration
The addition of trisodium citrate to heparinized
whole blood decreased iCa in a linear dose-dependent
manner: DiCa = 0.23 9 [citrate] - 0.21 (r2 = 0.97,
P = 0.002), with 1 mmol/L of citrate decreasing iCa by
0.23 mmol/L (95% CI, 0.16–0.30). The addition of cal-
cium chloride to citrated blood increased iCa in a linear
dose-dependent manner: DiCa = 0.62 9 [Ca] - 0.08
(r2 = 1.00, P = 0.004), with 1 mmol/L of calcium
increasing iCa by 0.62 mmol/L (95% CI, 0.45–0.79;
Fig 1).
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Fig 1. In vitro eﬀect of trisodium citrate (A) and calcium chloride (B) on ionized calcium concentration in canine blood from 5 clinically
healthy dogs. Data are represented as mean  standard deviation. (A) the eﬀect of citrate on iCa concentration can be described with the
equation: change in iCa (mmol/L) = 0.23 9 citrate (mmol/L)  0.21 (R2 = 0.97, P = 0.002). (B) The eﬀect of calcium on iCa concentration
can be described with the equation: change in iCa (mmol/L) = 0.62 9 calcium (mmol/L)  0.08 (R2 = 1.00, P = 0.004).
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The infusion of 2.56 mmol citrate per liter of circulat-
ing blood therefore was calculated to decrease iCa by
0.8 mmol/L, according to the set goals. Considering the
metabolism of the remaining calcium citrate complexes,
the infusion of 0.85 mmol (60% of 1.41 mmol) calcium
chloride per liter of blood was estimated to be necessary
to correct iCa back to 1.0 mmol/L. Based on these
data, initial citrate and calcium administration rates for
in vivo treatments were set to provide concentrations of
2.55 and 0.85 mmol/L blood, respectively. For a blood
ﬂow rate of 100 mL/min, trisodium citrate 102 mmol/L
therefore would be infused at a rate of 2.5 mL/min
(150 mL/h) and calcium chloride 340 mmol/L at a rate
of 0.25 mL/min (15 mL/h).
The main in vitro changes in electrolyte concentra-
tions and blood gas parameters obtained with the
citrate and calcium doses closest those selected for
in vivo use are summarized in Table 1. The addition of
trisodium citrate led to a marked increase in anion gap
but only to minimal alterations in acid-base status.
Recalciﬁcation with calcium chloride led to a marked
decrease in sodium concentration and moderate alka-
lemia, mostly as a consequence of decreased pCO2.
Animals and Diseases
One-hundred seventy-two dogs diagnosed with AKI
and treated with intermittent HD were enrolled in the
study, including 137 pure-breed dogs from 65 diﬀerent
breeds and 35 mixed-breed dogs. Sex distribution con-
sisted of 80 intact males (47%), 40 castrated males
(23%), 15 intact females (9%), and 37 spayed females
(22%). Median age at presentation was 6.0 years (IQR,
2.3–8.8 years), and median body weight was 22.2 kg
(IQR, 11.7–29.4 kg; range, 2.1–74.2 kg). The etiology of
AKI was identiﬁed as leptospirosis in 120 dogs (70%),
grape toxicity in 10 dogs (6%), other nephrotoxicoses
in 8 dogs (5%), and other causes of AKI in 34 dogs
(20%). The AKI grading (Appendix S3) at admission
indicated 8 dogs in grade 3 (5%), 78 dogs in grade 4
(45%), and 86 dogs in grade 5 (50%). Maximal grade
during hospitalization was grade 3 for 3 dogs (2%),
grade 4 for 72 dogs (42%), and grade 5 for 97 dogs
(56%). In 64 dogs (37%; 51 with leptospirosis and 13
with other etiologies), liver involvement was diagnosed,
with a peak serum bilirubin concentration of 4.0 mg/dL
(IQR, 1.3–11.7 mg/dL). Leptospirosis-associated pul-
monary hemorrhages were suspected radiologically in
92 dogs (53%), and risk of bleeding associated with sys-
temic hemostatic disorders was recognized by thrombo-
cytopenia or prolonged coagulation times in 115 dogs
(67%). Altogether, they accounted for 142 dogs (83%)
in which SH was strongly contraindicated.
HD Treatments
A median of 3 (IQR, 2–4) HD treatments with RCA
were performed in 172 dogs, resulting in 584 treatments
included in the study. Initially, 66 pilot treatments were
performed with additional SH, with heparin adminis-
tered in 5 dogs using a standard protocol of initial
bolus and full-dose CRI (resulting in 283 U/kg [IQR,
140–299 U/kg]) in 25 dogs with initial bolus and low-
dose CRI (18 U/kg [IQR, 13–21 U/kg]), in 35 dogs with
initial bolus only (IQR, 15 U/kg [7–33 U/kg]), and in 1
dog with low-dose CRI only (64 U/kg).
In the ﬁrst 19 pilot treatments, citrate was injected
through the heparin line of the extracorporeal circuit,
but for later treatments was changed to the most proxi-
mal site accessible, the inﬂow connection of the dialysis
catheter, because of excessive clotting proximal to the
injection site. Similarly, calcium injection was moved
distally from the venous drip chamber (ﬁrst 8 pilot
treatments) to the outﬂow connection of the dialysis
catheter.
Evaluation of safety and eﬃcacy of the RCA proto-
col was based on the last 518 treatments performed
with the ﬁnal heparin-free protocol. This group
included 156 ﬁrst dialysis treatments (30%), 129 second
treatments (25%), 97 third treatments (19%), and 136
Table 1. In vitro acid-base and electrolyte changes with citration and recalciﬁcation of venous blood (n = 5).
Native blood
+ Citrate + Citrate and calcium
2.93 mmol/L (Citrate)
2.93 mmol/L (Citrate) + 0.85 mmol/
L (Calcium)
P P
pH 7.46 (7.45 to 7.46) 7.45 (7.44 to 7.49) 0.526 7.55 (7.50 to 7.55) 0.007
HCO3 (mmol/L) 21.6 (21.5 to 22.5) 19.7 (18.0 to 19.9) 0.014 21.2 (20.6 to 21.3) 0.001
BE (mmol/L) 1.2 (1.6 to 1.2) 3.2 (3.6 to 3.2) 0.003 4.0 (4.7 to 3.9) 0.003
pCO2 (mmHg) 31.6 (31.1 to 34.1) 30.1 (24.3 to 30.3) 0.044 18.4 (18.2 to 18.5) 0.001
AG (mmol/L) 18.4 (17.7 to 19.3) 28.6 (27.3 to 29.0) <0.001 24.8 (22.2 to 26.5) 0.001
Na (mmol/L) 150.9 (150.4 to 150.9) 153.0 (152.9 to 153.6) 0.006 143.0 (142.8 to 144.4) 0.005
K (mmol/L) 3.87 (3.41 to 3.99) 3.58 (3.26 to 3.61) 0.005 3.46 (3.15 to 3.50) 0.001
iCa (mmol/L) 1.30 (1.27 to 1.30) 0.41 (0.37 to 0.43) <0.001 0.73 (0.70 to 0.73) <0.001
HCO3 , bicarbonate; BE, base excess; pCO2, CO2 partial pressure; AG, anion gap; Na, sodium; K, potassium; iCa, ionized calcium.
The doses of citrate (2.93 mmol/L) and calcium (0.85 mmol/L) were the closest to those selected for in vivo use (2.55 and 0.85 mmol/L,
respectively). Data are presented as median (IQR). P, statistical signiﬁcance for paired comparisons with native blood in Wilcoxon Signed-
Rank Test.
4 Francey and Schweighauser
later treatments (26%). Neonatal extracorporeal lines
were used for 157 treatments (30%), pediatric lines for
256 treatments (49%), and adult lines for 105 treat-
ments (20%). Dialyzers Polyﬂux 2H were prescribed for
72 treatments (14%), Polyﬂux 6H for 63 treatments
(12%), Polyﬂux 140H for 96 treatments (19%), Reva-
clear for 29 treatments (6%), Evodial 1.0 for 120 treat-
ments (23%), FSX paed for 13 treatments (3%), FX40
for 47 treatments (9%), FX50 for 40 treatments (8%),
FX60 for 26 treatments (5%), and FX100 for 12 treat-
ments (2%). The resulting extracorporeal blood volume
reached 129 mL (IQR, 88–182 mL) or 8.1% (IQR, 6.7–
10.2%) of the blood volume estimated at 8% of body
weight.
Dialysis parameters included a treatment time [Td] of
188 minutes (IQR, 156–227 minutes), an average blood
ﬂow rate [Qb] of 97 mL/min (IQR, 55–152 mL/min),
and a total volume of blood processed [Qp] of 17.2 L
(IQR, 8.9–33.2 L) or 0.85 L/kg (IQR, 0.47-1.44 L/kg),
with progressively increasing intensity after the initial
treatments (Table 2). Resulting average extracorporeal
blood residence time was 81 seconds (IQR, 63–117 sec-
onds; range, 18–593 seconds). Median net ﬂuid balance
was neutral with a change in body weight of 0.00 kg
(IQR, 0.30 to 0.12 kg) over the course of treatment.
Changes of Laboratory Variables with HD and
Adjustments of Citrate and Calcium Infusion Rates
The ﬁrst iCa control at 30 minutes of therapy was
reached in 513/518 RCA treatments (99%). This control
was not available for 5 dogs because of early discontinu-
ation for excessive clotting (n = 2), catheter dysfunction
(n = 1), or severe cardiopulmonary complication (n = 2).
Twelve additional measurements were not available
because of technical problems with the blood gas
analyzer. Results of iCa monitoring and adjustments of
the infusion rates of citrate and calcium are summarized
in Table 3 and Figure 2. Adjustments at 30 minutes of
therapy were more commonly required in the ﬁrst than
in later RCA treatments. Whiles monitoring of iCa in
the extracorporeal circuit predialyzer often led to adjust-
ments of the citrate infusion rate, its monitoring postdia-
lyzer was rarely useful, with 272/274 (99.3%)
measurements in the target range. Of all the 864 S1 mea-
surements (iCa in the dog) performed during these 518
treatments, only 20 (2.3%) were in a range of potential
risk for hypocalcemic complication (<0.7 mmol/L), 4 of
them (0.5%) being <0.6 mmol/L. Most of these hypocal-
cemic events were recorded at the beginning of the treat-
ment (14/20) and during the ﬁrst HD treatment for an
individual dog (9/20). None was associated with any clin-
ical manifestations of hypocalcemia, but vomiting was
observed in 3 of these occurrences.
Overall, 50% of the RCA treatments (259/518) necessi-
tated adjustments of citrate or calcium infusion rates or
both. After adjustments were performed, the ﬁnal citrate
and calcium infusion rates for the 518 HD treatments
both were slightly increased from the initial 2.55 (IQR,
2.55–2.81) and 0.85 (IQR, 0.85–0.96) mmol/L to 2.66
(IQR, 2.55–2.89) and 0.91 (IQR, 0.85–1.02) mmol/L
blood, respectively.
The eﬀects of HD with RCA on relevant biochemical
and blood gas variables are summarized in Table 4.
Total calcium concentration changed 0.92 mg/dL
(IQR, 1.88 to +0.04 mg/dL) [0.23 mmol/L (IQR,
0.47 to +0.01) mmol/L] (P < 0.001), decreasing the
proportion of total hypercalcemia from 28 to 16%
(P < 0.001) and increasing the proportion of total
hypocalcemia from 28% pre-HD to 52% post-HD
(P < 0.001). The decrease in total calcium concentration
was mainly due to a change in the calcium gap, the
Table 2. Main characteristics of the 518 heparin-free HD treatments performed with the ﬁnal RCA protocol.
Treatment
Tx 1 Tx 2 Tx 3 Tx > 3
P(n = 156) (n = 129) (n = 97) (n = 136)
Treatment duration (min) 150 (119 to 164) 188 (180 to 210) 210 (180 to 243) 240 (206 to 251) <0.001
Blood processed (L/kg) 0.41 (0.36 to 0.45) 0.76 (0.68 to 0.85) 1.31 (1.10 to 1.47) 1.68 (1.37 to 1.99) <0.001
Body weight (kg)
Pre 21.7 (11.0 to 28.7) 21.3 (11.0 to 28.6) 21.9 (12.0 to 28.2) 22.9 (17.3 to 29.9) 0.47
Post 21.7 (11.0 to 28.7) 21.2 (11.0 to 28.5) 21.4 (11.9 to 28.3) 22.6 (16.6 to 29.8) 0.49
Delta 0.0 (0.2 to 0.2) 0.1 (0.3 to 0.1) 0.0 (0.3 to 0.1) 0.0 (0.3 to 0.2) 0.58
PCV (%) [ref. 40–55]
Pre 31.5 (26.0 to 37.0) 30.0 (25.0 to 34.0) 30.0 (24.0 to 35.5) 27.0 (22.0 to 35.8) 0.046
Post 30.0 (25.0 to 35.0) 29.0 (24.0 to 33.3) 28.0 (22.5 to 33.0) 25.0 (20.0 to 32.0) 0.004
Urea (mg/dL) [ref. 17.4–66.7]
Pre 380 (330 to 501) 299 (235 to 359) 198 (150 to 243) 172 (129 to 216) <0.001
Post 222 (186 to 292) 105 (78 to 148) 38 (28 to 60) 25 (15 to 37) <0.001
URR 0.41 (0.37 to 0.47) 0.63 (0.58 to 0.69) 0.79 (0.74 to 0.83) 0.86 (0.79 to 0.90) <0.001
Creatinine (mg/dL) [ref. 0.5–1.6]
Pre 10.2 (8.0 to 12.3) 8.6 (7.2 to 10.5) 7.2 (6.0 to 8.3) 7.8 (6.6 to 9.2) 0.008
Post 6.4 (4.8 to 7.7) 3.8 (2.9 to 4.7) 2.2 (1.6 to 2.7) 1.8 (1.4 to 2.5) <0.001
CrRR 0.37 (0.34 to 0.42) 0.56 (0.51 to 0.61) 0.70 (0.65 to 0.74) 0.76 (0.70 to 0.82) <0.001
Tx, treatment; PCV, packed cell volume; URR, urea reduction ratio; CrRR, creatinine reduction ratio.
Data are presented separately for ﬁrst, second, third, and later treatments, as median (IQR). P, statistical signiﬁcance for comparison
between groups in Kruskal–Wallis one-way ANOVA.
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nonionized form of Ca, of 0.24 mmol/L (IQR, 0.46
to 0.01 mmol/L; P < 0.001). There was no net change
of iCa with a DiCa of 0.00 mmol/L (IQR, 0.10 to
+0.13 mmol/L; P = 0.3). Although the proportion of
ionized hypercalcemia increased from 6/501 (1.2%) pre-
HD to 24/500 (4.8%) post-HD (P < 0.001), most of
these changes remained minimal with iCa between 1.4
and 1.5 mmol/L (pre: 4/6, post: 17/24). The ratio of
total to ionized calcium, typically used to indicate
citrate toxicity in humans when >2.5, decreased from
2.41 (IQR, 2.18–2.73) to 2.14 (IQR, 2.00–2.34). The
limit of 2.5 was exceeded in 207/501 (41.3%) treatments
before and 81/493 (16.4%) treatments after therapy.
Relevant changes in blood gas parameters with the
treatments were as follows: DpH = +0.021 (IQR, 0.024
to +0.079; P < 0.001), Dbicarbonate = +1.3 mmol/L
(IQR, 0.5 to +3.0 mmol/L; P < 0.001), DpCO2 =
+0.35 mmHg (IQR, 3.4 to +5.5 mmHg; P < 0.001),
and Danion gap = 8.8 mmol/L (IQR, 11.2 to
6.5 mmol/L; P < 0.001).
Activated clotting time (ACT) was slightly lower
post-HD compared to pre-HD with a change of 4 sec-
onds (IQR, 16 to +4 seconds; P < 0.001), a slight but
clinically irrelevant improvement in coagulation.
Safety and Eﬃcacy of the RCA Procedure
Five hundred of 518 treatments (96.5%) could be
completed successfully. Nine treatments (1.7%) had to
be stopped early because of system clotting, 6 (1.2%)
due to catheter-related (n = 4) or because of other tech-
nical problems (n = 2), and 3 (0.6%) as a consequence
of fatal worsening of leptospirosis-associated pulmonary
hemorrhages (n = 2) or cardiovascular failure (n = 1)
(Table 5). Minor complications not requiring discontin-
uation of the procedure were observed in 19 additional
treatments (3.7%). They included catheter dysfunction
(n = 7, 1.4%) or other technical problems (n = 1,
0.2%), respiratory (n = 4, 0.8%) or cardiovascular
(n = 4, 0.8%) complications, and 1 case each (0.2%) of
fever, abdominal pain, and severe excitation. Therefore,
481 treatments (92.9%) were completed without
complications.
Fatalities were observed during dialysis in 3 dogs
(0.6%) and within 24 hours of treatment completion in
7 other dogs (1.4%). All fatalities were direct complica-
tions of the underlying cause of AKI, and none was
directly or indirectly associated with the RCA proce-
dure. Eight of these events were caused by worsening of
leptospirosis-associated pulmonary hemorrhages, 1 by
cardiovascular failure, and 1 by rupture of multiple
intestinal intussusceptions. None of the classical clinical
Table 3. Results of the iCa monitoring during 518 HD
treatments performed with RCA and adjustments per-
formed to the infusion rates of trisodium citrate and
calcium chloride.
First RCA Tx
n = 159
Later RCA Tx
n = 359 P
iCa on target at ﬁrst measurement (30 min)
Dog (S1) 122/154
79%
300/348
86%
0.049
Circuit,
predialyzer (S2)
113/154
73%
307/346
89%
<0.001
Circuit,
postdialyzer (S3)
76/77
99%
196/197
99%
0.50
Adjustments to citrate infusion rate
Increased
Changes (n) 64 84
Treatments with
changes (%)
57 (36%) 72 (20%) <0.001
Decreased
Changes (n) 3 19
Treatments with
changes (%)
3 (2%) 17 (5%) 0.12
Adjustments to calcium infusion rate
Increased
Changes (n) 69 128
Treatments with
changes (%)
51 (32%) 103 (29%) 0.44
Decreased
Changes (n) 3 23
Treatments with
changes (%)
3 (2%) 22 (6%) 0.03
All adjustments
Changes (n) 139 254
Treatments with
changes (%)
99 (62%) 160 (45%) <0.001
RCA, regional citrate anticoagulation; Tx, treatment; iCa, ion-
ized calcium; S1, blood sampled from the dog; S2, blood sampled
from the extracorporeal circuit, predialyzer; S3, blood sampled
from the extracorporeal circuit, postdialyzer.
P, statistical signiﬁcance for comparison of proportions between
ﬁrst and later RCA treatments in Chi-Square Test.
Tx1
0.00
0.40
0.80
1.20
1.60
Io
ni
ze
d 
C
al
ci
um
 C
on
ce
nt
ra
tio
n 
(m
m
ol
/l)
Tx >1 Tx1 Tx >1 Tx1 Tx >1
Dog Circuit
Pre-Dialyzer
Circuit
Post-Dialyzer
P=0.26
P=0.002
P=0.004
Fig 2. Box plot representation of the blood iCa concentration
measured from the dogs and from the extracorporeal circuits
(pre- and postdialyzer) 30 minutes after initiation of HD in 518
treatments with RCA. First treatments (white boxes, n = 159) are
compared to later treatments (gray boxes, n = 359), Mann-Whitney
U-test. Shaded areas represent the target iCa concentration for the
corresponding samples.
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signs associated with hypocalcemia were noted at any
time during the treatments in the dogs dialyzed with
RCA.
Changes in dialyzer ﬂow characteristics were noticed
by an increase in dialyzer pressure gradient of 6.5%
(IQR, 3.7 to 17.3%, P < 0.001) from baseline. Dia-
lyzer ﬁltration function was only minimally aﬀected
with an eﬀective URR of 104% (IQR, 99–110%) of the
expected URR and an eﬀective CrRR of 91% (IQR,
82–96%) of the expected CrRR. The extracorporeal
Table 4. Changes of calcium concentration, main venous blood gas parameters, and activated clotting time with
HD in dogs treated with RCA (n = 518 treatments).
Tx 1 Tx 2 Tx 3 Tx > 3
P(n = 156) (n = 129) (n = 97) (n = 136)
TCa (mg/dL)
[ref. 10.0–11.7]
Pre 10.1 (9.2–11.2) 10.2 (9.4–11.2) 10.4 (9.7–11.2) 11.4 (10.3–13.3) <0.001*
Post 9.3 (8.5–10.4) 9.2 (8.3–10.5) 9.6 (8.6–10.4) 10.2 (9.3–11.4) <0.001*
TCa (mmol/L)
[ref. 2.50–2.93]
Pre 2.53 (2.30–2.81) 2.55 (2.36–2.81) 2.59 (2.42–2.81) 2.86 (2.57–3.32) <0.001*
Post 2.32 (2.12–2.61) 2.30 (2.07–2.63) 2.40 (2.15–2.60) 2.56 (2.33–2.85) <0.001*
P (pre-post) <0.001* <0.001* <0.001* <0.001*
iCa (mmol/L)
[ref. 1.20–1.40]
Pre 1.12 (0.96–1.21) 1.09 (0.98–1.17) 1.12 (1.03–1.21) 1.13 (1.05–1.23) 0.052
Post 1.06 (0.98–1.17) 1.10 (1.00–1.22) 1.10 (1.02–1.18) 1.14 (1.05–1.23) 0.002*
P (pre-post) 0.87 0.054 0.48 0.10
Non-iCa (mmol/L)
[ref. 1.30–1.50]
Pre 1.46 (1.21–1.68) 1.48 (1.29–1.77) 1.50 (1.30–1.72) 1.76 (1.45–2.10) <0.001*
Post 1.25 (1.08–1.49) 1.18 (1.02–1.46) 1.29 (1.09–1.43) 1.41 (1.21–1.68) <0.001*
P (pre-post) <0.001* <0.001* <0.001* <0.001*
pH
[ref. 7.35–7.45]
Pre 7.30 (7.23–7.34) 7.30 (7.27–7.34) 7.31 (7.28–7.34) 7.33 (7.28–7.40) <0.001*
Post 7.32 (7.28–7.35) 7.33 (7.31–7.36) 7.35 (7.32–7.38) 7.36 (7.32–7.39) <0.001*
P (pre-post) <0.001* <0.001* <0.001* 0.006*
HCO3 (mmol/L)
[ref. 20–24]
Pre 17.4 (14.2–19.6) 17.2 (15.5–19.7) 18.3 (16.2–20.2) 17.6 (15.8–21.0) 0.029*
Post 18.4 (16.8–20.1) 19.5 (18.0–21.2) 20.4 (18.9–21.9) 20.8 (19.5–22.4) <0.001*
P (pre-post) <0.001* <0.001* <0.001* <0.001*
pCO2 (mmHg)
[ref. 35–45]
Pre 36.2 (32.6–40.3) 36.6 (34.2–39.6) 37.5 (34.3–41.9) 35.1 (30.3–39.8) 0.011*
Post 37.8 (34.7–40.2) 37.9 (34.6–40.4) 38.1 (35.6–40.6) 38.4 (34.8–41.1) 0.53
P (pre-post) 0.19 0.011* 0.88 <0.001*
Anion Gap (mmol/L)
[ref. 8–12]
Pre 26.2 (21.8–31.4) 22.7 (20.0–26.5) 19.4 (17.1–22.5) 20.8 (18.0–24.7) <0.001*
Post 17.8 (14.8–21.5) 13.1 (10.9–15.8) 11.7 (9.7–13.7) 10.6 (8.9–13.2) <0.001*
P (pre-post) <0.001* <0.001* <0.001* <0.001*
ACT(s)
[ref. 60–90]
Pre 111 (101–133) 111 (101–129) 113 (98–125) 107 (101–128) 0.96
Post 112 (99–123) 105 (98–118) 105 (94–115) 102 (92–118) 0.068
P (pre-post) 0.50 0.013* 0.011* <0.001*
Mg (mg/dL)
[ref. 1.53–2.33]
Pre 2.99 (2.38–3.38) 2.89 (2.45–3.23) 2.72 (2.43–3.04) 2.65 (2.36–2.96) 0.002*
Post 2.43 (2.24–2.67) 2.21 (2.07–2.36) 2.09 (1.92–2.21) 1.94 (1.82–2.19) <0.001*
P (pre-post) <0.001* <0.001* <0.001* <0.001*
Tx, treatment; TCa, total calcium concentration; iCa, ionized calcium concentration; HCO3 , serum bicarbonate concentration; pCO2,
CO2 partial pressure; ACT, activated coagulation time; Mg, magnesium.
Data are presented separately for ﬁrst, second, third, and later treatments, as median (IQR). P, statistical signiﬁcance for comparison
between groups in Kruskal–Wallis one-way ANOVA; P(pre-post), statistical signiﬁcance for paired comparisons before and after HD in
Wilcoxon Signed-Rank Test. Statistically signiﬁcant diﬀerences are indicated with *.
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circuits of 513 treatments could be inspected visually
after blood rinseback. No visible clotting overall was
observed in 96 (19%) circuits. Minimal clotting was
found in 376 (73%) circuits, moderate clotting in 35
(7%) circuits, and severe clotting in 6 (1%) circuits.
Overall, anticoagulation was judged very good in 372
treatments (72%), associated with minor grade compli-
cations in 100 (19%), moderate grade complications in
26 (5%), and severe grade complications in 17 (3%)
treatments. Moderate and severe grade complications
more often were encountered in small dogs and during
early treatments (both P < 0.001). Accordingly, pre-
treatment urea (P < 0.001) and creatinine (P < 0.01)
concentrations were higher, total calcium concentration
(P = 0.04) was lower, average blood ﬂow (P < 0.001)
was lower, extracorporeal blood residence time
(P < 0.001) was longer, and URR (P < 0.001) and
CrRR (P < 0.001) were lower in problem treatments.
Discussion
Our data establish for the ﬁrst time a safe and eﬃ-
cient RCA protocol for intermittent HD developed
speciﬁcally for dogs. The administration of citrate in
the extracorporeal blood circuit immediately chelates
divalent cations. The decrease in iCa inhibits the func-
tion of several calcium-dependent factors, disrupting
important mechanisms of platelet adhesion, and activa-
tion as well as the intrinsic and extrinsic pathways of
the coagulation cascade.18 The established protocol was
associated with minimal complications in a very small
number of treatments. Anticoagulation was very eﬃca-
cious and yielded satisfactory results in >90% of the
heparin-free treatments, allowing HD treatment in dogs
at risk of or with active bleeding.
The 2-stage study design with in vitro titration experi-
ments ﬁrst on normal canine blood followed by in vivo
heparin-free RCA in a large group of dogs at risk of
bleeding proved successful and relevant for establishing
the deﬁnitive protocol to be used in dogs. The initial
use of the protocol in pilot dogs under additional SH
allowed us to evaluate its safety and eﬃcacy separately.
The eﬀectively used citrate and calcium infusion rates
after adjustments diﬀered only minimally from the
starting ﬂow rates, conﬁrming further the validity of the
calculations. The monitoring protocol and the adjust-
ments performed largely were adapted from similar pro-
tocols used in humans and proved very appropriate for
use in the dog, as can be seen in the large proportion of
successful treatments. The simple calculation of the ini-
tial citrate and calcium ﬂow rates used in our study has
been preferred for other slightly more complex
calculations including predialysis hematocrit, total pro-
tein concentration, and total calcium concentrations to
determine the infusion rates of citrate and calcium, a
decision supported by good eﬃcacy results.17
One of the main practical diﬀerences between SH and
RCA is the necessity to monitor iCa repeatedly during
treatment. Because doing so replaces monitoring of
coagulation times, it does not require removal of addi-
tional blood volume, but it may increase monitoring
costs, depending on the system available. The large
number of treatments (50%) requiring adjustments of
ﬂow rates of citrate, calcium or both clearly emphasizes
this necessity, especially in the ﬁrst treatments. The
number of adjustments possibly could be decreased by
increasing the starting citrate and calcium infusion rates
by +4 and +7%, respectively, based on the ﬁnal infusion
rates achieved for the study dogs.
As opposed to SH, the infusion rates of citrate and cal-
cium are functions of the blood ﬂow rate and must be
changed or stopped accordingly. Failure to do so may
quickly result in excessive citrate infusion and cause fatal
arrhythmias.19 With insuﬃcient calcium administration,
hypocalcemia is more likely to result in neuromuscular
complications before arrhythmias are observed. Insuﬃ-
cient citrate and excessive calcium infusion rates may
result in clotting of the extracorporeal circuit and sub-
stantial blood loss from the animal. These severe and
potentially fatal complications should be kept in mind,
and attention should be given to the appropriate func-
tion of the whole system, particularly in very small
patients with small catheter volumes and very large
patients with high citrate and calcium infusion rates.
Some continuous renal replacement therapy machines
have incorporated automated RCA modules, eliminating
the need for manual adjustments of the citrate and cal-
cium pumps. Such systems are increasingly available on
intermittent HD platforms and will represent a relevant
safety advantage in the near future. However, our study
clearly shows that these risks should not be overempha-
sized, provided appropriate monitoring is carried out,
and no such complication was observed in 518 treatments
on a wide range of canine sizes and blood ﬂow rates.
Major metabolic complications resulting from abso-
lute or relative excess in trisodium citrate administration
were rarely encountered in dogs treated with the
described protocol. Hypernatremia and metabolic alka-
losis were never observed in the study treatments.
Citrate toxicity with total hypercalcemia and ionized
hypocalcemia resulting from citrate accumulation from
excessive infusion rate or insuﬃcient metabolism was
never recognized clinically. Increased postdialysis cal-
cium gap and a TCa:iCa ratio >2.5 often are used in
Table 5. Eﬃcacy of anticoagulation performed with a RCA in dogs undergoing HD (n = 518 treatments).
Tx Completion
Dialyzer ΔP
Increase < 25%
Eﬀective URR
≥75% From Expected
Eﬀective CrRR
≥75% From Expected
Visual Scoring
Score ≤ 4
Successful 500/518 (97%) 266/323 (82%) 483/506 (95%) 435/506 (86%) 472/513 (92%)
Unsuccessful 18/518 (3%) 57/323 (18%) 23/506 (5%) 71/506 (14%) 41/513 (8%)
Tx, treatment; DP, hydrostatic pressure gradient; URR, urea reduction ratio; CrRR, creatinine reduction ratio.
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humans as evidence of citrate toxicity. In these dogs,
both variables decreased signiﬁcantly during the treat-
ments, indicating a lack of accumulation of citrate-
calcium complexes. The predialysis TCa:iCa ratio, how-
ever, was >2.5 in >40% of the treatments, limiting the
use of this ratio to its relative change during the treat-
ment. Despite a short half-life in circulation,
the metabolism of citrate is located predominantly in
the liver, in the skeletal muscle, and in the kidney,20
and causes citrate anticoagulation to be relatively con-
traindicated in humans with renal and liver insuﬃ-
ciency. However, no evidence of citrate toxicity was
recognized in dogs with kidney and liver disease, even
in those aﬀected with leptospirosis and combined severe
renal and hepatic involvement, in which RCA was used
safely. This observation probably reﬂects the high clear-
ance rate of the procedure, with removal of most of the
remaining citrate by the dialyzer. At the extremes of
body weight, such dogs should, however, still be moni-
tored more closely for the occurrence of citrate toxicity.
Other hematologic and metabolic eﬀects of citrate
anticoagulation were not evaluated further in our study.
Considering the tight physiologic regulation of serum
iCa, it is possible that the interference caused by the
RCA technique may aﬀect central metabolic pathways.
For example, even a minor change in iCa is likely to
alter parathyroid hormone production. In humans, a
low-iCa target facilitated reaching a less positive cal-
cium mass balance, however, at the expense of a signiﬁ-
cant increase in parathyroid hormone concentration.21
How far such short-term alterations add to the marked
dysregulation of calcium and phosphate metabolism in
AKI patients remains to be evaluated.
Both heparin and citrate have been reported to aﬀect
the pro- versus anti-inﬂammatory balance diﬀerently,
depending on the model used.22,23 They are postulated
to inﬂuence the inﬂammatory response either directly or
through some of its key mediators. For example, RCA
was shown to help decrease leukocyte and monocyte
activation during passage through the extracorporeal
circuit.24 On the other hand, insuﬃcient anticoagulation
can result in activation of platelets and the coagulation
cascade and thus cause additional inﬂammation, consid-
ering the intricate links between hemostasis and inﬂam-
mation. Evaluation of these aspects was beyond the
scope of our study and should be investigated in speciﬁ-
cally designed prospective studies.
One of the main limitations of our study was the
absence of a comparison group with standard SH, espe-
cially for the evaluation of safety and eﬃcacy. Unfortu-
nately, with 83% of dogs in which heparinization was
contraindicated, a 2-group design would have resulted
in a severe selection bias with marked diﬀerences in eti-
ologies, inﬂammatory status, hemostatic disorders, and
disease severity between the groups. We chose therefore
to concentrate on the development of a safe and eﬃ-
cient citrate anticoagulation protocol and on a detailed
description of its eﬀects.
In conclusion, the established RCA protocol
(Appendix S4) opens the possibility to safely dialyze
dogs with active bleeding, at high risk of bleeding, or
in need of immediate surgery. Considering that the
main indication for HD in veterinary medicine is AKI
and that hemostatic disorders are frequent in this
group of patients, this approach represents a major
advance for blood puriﬁcation techniques in critically
ill dogs.
Footnotes
a Trisodium citrate 30 g/L, 102 mmol/L, Dr G. Bichsel Labora-
tory, Interlaken, Switzerland
b Calcium chloride 50 g/L, 340 mmol/L, Dr G. Bichsel Labora-
tory
c RAPIDPoint 400, Siemens Health Care Diagnostics, Zurich,
Switzerland
d Gambro Hospal (Switzerland), Kilchberg, Switzerland
e Lines A-5/V-5 (priming volume, 33 mL), BL121P (100 mL),
BL200 BD (151 mL); Gambro Hospal (Switzerland)
f Filters Polyﬂux 2H (surface area, 0.2 m2; blood priming volume,
18 mL), Polyﬂux 6H (0.6 m2; 52 mL) Polyﬂux 140H (1.4 m2;
75 mL), Revaclear (1.4 m2, 84 mL), Evodial 1.0 (1.0 m2; 66 mL),
Gambro Hospal (Switzerland)
Filters FX paed (0.2 m2; 18 mL), FX40 (0.6 m2; 32 mL), FX50
(1.0 m2; 53 mL), FX 60 (1.4 m2; 74 mL), FX 100 (2.2 m2;
116 mL); Fresenius Medical Care (Switzerland), Oberdorf,
Switzerland
Membrane material—Polyﬂux ﬁlters: Polyﬂux membrane (pol-
yarylether sulfone/polyvinyl pyrrolidone/polyamide); Revaclear
ﬁlter: Poracton membrane (polyarylether sulfone/polyvinyl
pyrrolidone); Evodial ﬁlter: HeprAN membrane (heparin-grafted
acrylonitrile—sodium methallyl sulfonate copolymer/polyethyle-
neimine, AN69ST); Fresenius ﬁlters: Helixone membrane (Frese-
nius Polysulfone based)
g Dialysate A341G; Dr G. Bichsel Laboratory
h Microsoft Excel 2010, (Version 14.0.7188.5000); Microsoft
Corporation, Redmond, WA
i NCSS 9.0.15; NCSS, LLC, Kaysville, UT
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Supporting Information
Additional Supporting Information may be found
online in Supporting Information:
Appendix S1. Assessment criteria used for the evalua-
tion of treatment eﬃcacy.
Appendix S2. Modeling parameters of expected URR
and CrRR using standard heparinisation in 233 HD
treatments for AKI in canines.
Appendix S3. IRIS grading system for dogs with
acute kidney injury (AKI).
Appendix S4. Proposed treatment protocol for regio-
nal citrate anticoagulation in dogs on intermittent
hemodialysis.
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